194 related articles for article (PubMed ID: 16611121)
1. Recent advances in antiviral agents: antiviral drug discovery for hepatitis viruses.
Tanikawa K
Curr Pharm Des; 2006; 12(11):1371-7. PubMed ID: 16611121
[TBL] [Abstract][Full Text] [Related]
2. [Interferon].
Tamori A; Kawada N
Nihon Rinsho; 2012 Apr; 70(4):620-4. PubMed ID: 22568143
[TBL] [Abstract][Full Text] [Related]
3. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
[TBL] [Abstract][Full Text] [Related]
4. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin.
Potthoff A; Berg T; Wedemeyer H;
Scand J Gastroenterol; 2009; 44(12):1487-90. PubMed ID: 19900055
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and current management of hepatitis B and C in China.
Sun YT; Zhang YX; Tang H; Mao Q; Wang XZ; Zhang LY; Chen H; Zhong YN; Lin SM; Zhang DZ
World J Gastroenterol; 2014 Oct; 20(37):13582-90. PubMed ID: 25309089
[TBL] [Abstract][Full Text] [Related]
6. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
Delaney WE; Locarnini S; Shaw T
Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection.
Rautou PE; Asselah T; Saadoun D; Martinot M; Valla D; Marcellin P
Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):1019-22. PubMed ID: 16894318
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance in antiviral treatment for infections with hepatitis B and C viruses.
Yotsuyanagi H; Koike K
J Gastroenterol; 2007 May; 42(5):329-35. PubMed ID: 17530355
[TBL] [Abstract][Full Text] [Related]
9. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection.
Yeh ML; Hsieh MY; Huang CI; Huang CF; Hsieh MH; Huang JF; Dai CY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2016 Apr; 31(4):835-41. PubMed ID: 26478984
[TBL] [Abstract][Full Text] [Related]
11. A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses.
Shakya N; Vedi S; Liang C; Agrawal B; Tyrrell DL; Kumar R
Bioorg Med Chem Lett; 2012 Oct; 22(20):6475-80. PubMed ID: 22985854
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B and C viruses: molecular identification and targeted antiviral therapies.
Berenguer M; Wright TL
Proc Assoc Am Physicians; 1998; 110(2):98-112. PubMed ID: 9542765
[TBL] [Abstract][Full Text] [Related]
14. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.
Meuleman P; Leroux-Roels G
Antiviral Res; 2008 Dec; 80(3):231-8. PubMed ID: 18706933
[TBL] [Abstract][Full Text] [Related]
15. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.
Korba BE; Montero AB; Farrar K; Gaye K; Mukerjee S; Ayers MS; Rossignol JF
Antiviral Res; 2008 Jan; 77(1):56-63. PubMed ID: 17888524
[TBL] [Abstract][Full Text] [Related]
16. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
17. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy.
Hung CH; Chen CH; Lu SN; Wang JH; Hu TH; Huang CM; Tsai MC; Lee CM
Antiviral Res; 2012 Jan; 93(1):55-63. PubMed ID: 22061616
[TBL] [Abstract][Full Text] [Related]
18. [Anti-hepatitis B virus drugs].
Minami M
Nihon Rinsho; 2012 Apr; 70(4):609-13. PubMed ID: 22568141
[TBL] [Abstract][Full Text] [Related]
19. Drug-resistant viral hepatitis.
Wright M; Main J; Thomas HC
J Infect; 2000 Jul; 41(1):1-4. PubMed ID: 10942634
[No Abstract] [Full Text] [Related]
20. Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives.
Sun D; Zhu L; Yao D; Chen L; Fu L; Ouyang L
Eur J Med Chem; 2018 Mar; 147():205-217. PubMed ID: 29438889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
